BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 9512674)

  • 1. Efficacy of intravenous granisetron to control nausea and vomiting during multiple cycles of cisplatin-based chemotherapy.
    Ritter HL; Gralla RJ; Hall SW; Wada JK; Friedman C; Hand L; Fitts D
    Cancer Invest; 1998; 16(2):87-93. PubMed ID: 9512674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of different doses of granisetron for the prophylaxis of cisplatin-induced emesis.
    Perez EA; Navari RM; Kaplan HG; Gralla RJ; Grunberg SM; Palmer RH; Fitts D
    Support Care Cancer; 1997 Jan; 5(1):31-7. PubMed ID: 9010987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin.
    Navari RM; Kaplan HG; Gralla RJ; Grunberg SM; Palmer R; Fitts D
    J Clin Oncol; 1994 Oct; 12(10):2204-10. PubMed ID: 7931490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy.
    Audhuy B; Cappelaere P; Martin M; Cervantes A; Fabbro M; Rivière A; Khayat D; Bleiberg H; Faraldi M; Claverie N; Aranda E; Auclerc G; Audhuy B; Benhammouda A; Bleiberg H; Cals L; Cappelaere P; Cattan A; Cervantes A; Chevallier B; Conroy T; Cupissol D; De Grève J; Diaz-Rubio E; Seitz JF
    Eur J Cancer; 1996 May; 32A(5):807-13. PubMed ID: 9081358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
    Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
    Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group.
    Navari R; Gandara D; Hesketh P; Hall S; Mailliard J; Ritter H; Friedman C; Fitts D
    J Clin Oncol; 1995 May; 13(5):1242-8. PubMed ID: 7738628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study.
    Perez EA; Hesketh P; Sandbach J; Reeves J; Chawla S; Markman M; Hainsworth J; Bushnell W; Friedman C
    J Clin Oncol; 1998 Feb; 16(2):754-60. PubMed ID: 9469367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Granisetron. An update of its therapeutic use in nausea and vomiting induced by antineoplastic therapy.
    Yarker YE; McTavish D
    Drugs; 1994 Nov; 48(5):761-93. PubMed ID: 7530631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized study of the efficacy and safety of transdermal granisetron in the control of nausea and vomiting induced by moderately emetogenic chemotherapy in Korean patients.
    Kim JE; Hong YS; Lee JL; Kim KP; Park SJ; Sym SJ; Shin DB; Lee J; Park YS; Ahn JS; Kim TW
    Support Care Cancer; 2015 Jun; 23(6):1769-77. PubMed ID: 25465680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study.
    Seol YM; Kim HJ; Choi YJ; Lee EM; Kim YS; Oh SY; Koh SJ; Baek JH; Lee WS; Joo YD; Lee HG; Yun EY; Chung JS
    Support Care Cancer; 2016 Feb; 24(2):945-952. PubMed ID: 26265119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Control of delayed nausea and vomiting with granisetron plus dexamethasone or dexamethasone alone in patients receiving highly emetogenic chemotherapy: a double-blind, placebo-controlled, comparative study.
    Goedhals L; Heron JF; Kleisbauer JP; Pagani O; Sessa C
    Ann Oncol; 1998 Jun; 9(6):661-6. PubMed ID: 9681082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial.
    Mantovani G; Macciò A; Bianchi A; Curreli L; Ghiani M; Proto E; Santona MC
    Cancer; 1996 Mar; 77(5):941-8. PubMed ID: 8608488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
    Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
    Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy.
    Gralla RJ; Navari RM; Hesketh PJ; Popovic W; Strupp J; Noy J; Einhorn L; Ettinger D; Bushnell W; Friedman C
    J Clin Oncol; 1998 Apr; 16(4):1568-73. PubMed ID: 9552067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical evaluation of granisetron injection against nausea and vomiting induced by anticancer drugs including cisplatin].
    Yoshiya N; Kodama S; Tanaka K; Hataya I; Tokunaga A; Takeuchi Y; Hanaoka J; Yanase T; Takahashi T; Maruhashi T
    Gan To Kagaku Ryoho; 1994 Aug; 21(10):1641-6. PubMed ID: 8060140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Granisetron plus methylprednisolone for the control of high-dose cisplatin-induced emesis.
    Kleisbauer JP; García-Girón C; Antimi M; Azevedo MC; Balmes H; Massuti-Sureda B; Contu A; Luque A; Pellier P
    Anticancer Drugs; 1998 Jun; 9(5):387-92. PubMed ID: 9660534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical evaluation of 2 mg granisetron tablet for nausea and vomiting induced by anticancer drugs including cisplatin].
    Takada M; Furuse K; Fukuoka M; Kawahara M; Negoro S; Kusunoki Y; Ogawara M; Furue H
    Gan To Kagaku Ryoho; 1997 Jun; 24(8):987-94. PubMed ID: 9212809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparison of antiemetic efficacy of granisetron as premedication versus combination therapy of granisetron].
    Ikeda H; Koshiba R
    Gan To Kagaku Ryoho; 1998 Oct; 25(12):1947-53. PubMed ID: 9797818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of granisetron, ondansetron and tropisetron for control of vomiting and nausea induced by cisplatin.
    Oge A; Alkiş N; Oge O; Kartum A
    J Chemother; 2000 Feb; 12(1):105-8. PubMed ID: 10768522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-blind, crossover, randomized dose-comparison trial of granisetron for the prevention of acute and delayed nausea and emesis in children receiving moderately emetogenic carboplatin-based chemotherapy.
    Berrak SG; Ozdemir N; Bakirci N; Turkkan E; Canpolat C; Beker B; Yoruk A
    Support Care Cancer; 2007 Oct; 15(10):1163-8. PubMed ID: 17372773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.